Dowjones sẽ bay kha khá từ tối nay!

Dang nói DJ. Viết thế cho nó nhanh bác ạ

Khéo vụ fake news có 1 không hai
China hồi tháng 2 cũng dùng thuốc này
Nếu ngon nó đã la toáng lên

Gilead Pours Cold Water On Report That Sent Market Soaring: "Anecdotal Reports With No Statistical Power"

by Tyler Durden
Thu, 04/16/2020 - 20:35
TwitterFacebookRedditEmailPrint

Statnews published a report by Adam Feuerstein, best known for doing the bidding of one or more hedge fund clients, according to which a "Chicago hospital treating severe Covid-19 patients with Gilead Sciences’ antiviral medicine remdesivir in a closely watched clinical trial is seeing rapid recoveries in fever and respiratory symptoms, with nearly all patients discharged in less than a week, STAT has learned."

"Learned" from whom? A hedge fund or two who were long GILD and needed a fake news catalyst to get out? Because last time we checked, double blind, secret drug trials are, er... secret.

The report went on: "patients using Gilead's remdesivir were "seeing rapid recoveries in fever and respiratory symptoms", which is odd considering the two previous incomplete/failed trials in China. According to the report, "almost all patients were discharged in under than a week, and only two patients died."

the FT reported later - this time using facts not sources - "none of the patients on the Chicago trial had been on invasive ventilation", so is it possible that the drug killed them? Maybe Feuerstein can ask his hedge fund source.

In any case, at the time the data hit Bloomberg around 4:21pm, it barely registered among the institutional audience, or even the algos, as most serious players were well aware of Feuerstein's "tactical" reputation.



It wasn't until the news was reported by CNBC about 30 minutes later - and hit the retail investing audience - that GILD stock soared 16 and the entire market took off as if someone had suddenly discovered not only a cure but also a vaccine for coronavirus.

Alas, neither happened, and as it has done on numerous occasions previously, about three hours after the news broke conveniently providing one or more hedge funds ample opportunity to offload their position in the thin after hours market, Gilead issued a statement which suggested that STAT was pumping the stock based on nothing more than "anecdotal reports" to wit:


"We understand the urgent need for a Covid-19 treatment and the resulting interest in data on our investigational antiviral drug remdesivir. The totality of the data need to be analysed in order to draw any conclusions from the trial."

"Anecdotal reports, while encouraging, do not provide the statistical power necessary to determine the safety and efficacy profile of remdesivir as a treatment for Covid-19. We expect the data from our Phase 3 study in patients with severe Covid-19 infection to be available at the end of this month, and additional data from other studies to become available in May."

And so, one more attempt to ramp the market using fake news of an imminent drug has failed, with some observing that a Phase 1 drug trial is now the functional equivalent of a Phase 1 trade deal - both meaningless on their own, but with the power to send stocks surging when used tactically by unknown players.

Experts had high hopes for remdesivir because it had shown it was effective in stopping the Ebola virus replicating. Ebola shares a similar mechanism of replication with Sars-CoV-2, the virus that causes the Covid-19 disease. However, there has been no definitive statistic evidence yet that that is the case.



Investors should be cautious on the potential for Gilead’s drug Remdesivir, analysts say
PUBLISHED FRI, APR 17 20207:08 AM EDTUPDATED AN HOUR AGO

Julianna Tatelbaum




KEY POINTS

• The Barclays health-care team called the update “encouraging” but note that questions persist.
• Jefferies equity analyst Michael J. Yee published in a research note that this Chicago report provides an “incremental positive.”
• JPMorgan biotechnology equity analysts said that “this clinical trial experience appears to represent another encouraging, albeit largely anecdotal, data point for this high-profile drug candidate.”

WATCH NOW
VIDEO02:30
Coronavirus patients reportedly responding to Gilead’s experimental treatment

A new report from STAT News on Gilead’s experimental drug Remdesivir serves as an encouraging update on the drug’s potential to fight Covid-19, however analysts argue it’s largely anecdotal and should be interpreted with caution.

Remdesivir was one of the first medicines identified as a contender to treat Covid-19 given it showed promise in the past in treating SARS and MERS, both caused by coronaviruses.

According to the report from an ongoing phase three trial at a University of Chicago hospital, patients showing severe Covid-19 symptoms who were given the drug saw rapid recoveries in fever and respiratory symptoms, with nearly all patients discharged in less than one week.

Hôm nay chất gần 200k đỡ giá 99.00 VNM cả ngày, 99.1 thì ko chịu mua

--- Gộp bài viết, 17/04/2020, Bài cũ: 17/04/2020 ---

Mấy thằng cũ nhát gan đứng xem, tay to rut hết chân thì còn F0 hết về cứu banh bông

--- Gộp bài viết, 17/04/2020 ---

Bác lúc nãy chém nó đứt đầu rồi, cao thủ

tớ ko phân tích theo FA nên ko rành lam nhưng...hay đấy !
Đơn thuần các thị trường đang lên chạm lại 1 vùng rất mạnh đã đi qua, xu hướng khách quan đã chuyển sang giảm sau cú sụp đầu năm nay. Theo kn thì ở mấy vùng được đón chờ thế này mà tăng như vào chốn ko người thì bẫy buyer rất nhiều!

F0 hung hãn lắm. Còn cả đội lô đề,xổ số, cá độ bóng đá qua nữa. Bây giờ mấy ai quan tâm quỹ, Tây Lông bán ròng bao nhiêu đâu. Họ chỉ quan tâm các f0 thôi

Cụ thị trường bị đột quị nằm sàn, sau thời gian cụ ngồi lại đc. Hnay vừa húp tí nước luộc rau muống mà cụ đứng dậy được. Tuần sau con cháu cụ tin cụ leo được núi nữa

Tình hình thất nghiệp ở Mỹ đang khá thảm, nCoV thì cũng toang, DJ lại tăng bất chấp từ vùng đáy 18/3 thì khả năng giảm là khá cao.

Còn đối với mình thì HOSE thì lại là 1 câu chuyện khác. Vào full hàng từ 6xx giờ vẫn full hàng.

Nhớ thời điểm cuối 2017 cũng 1 mớ nhà đầu tư mới vào chào sàn, y như rằng cháo thì chưa húp nhưng răng ko còn!
Cứ lúc nào số member f319 tăng vọt là hãi lắm!

Nêú DJ ko bay thì xoá luôn nick đi nhé.

Kèo này T2 căng nhi?